SCHEMBL23580701

SCHEMBL23580701

COC1CN(C(=O)c2ncc(Br)cc2Cl)C1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
ADORA2A P29274 6/20 0.39
CYP11B2 P19099 1/20 0.36
ATR Q13535 2/20 0.36
RIPK1 Q13546 1/20 0.36
TTK P33981 1/20 0.36
HCRTR1 O43613 2/20 0.36
HCRTR2 O43614 2/20 0.36
GRIN2B Q13224 1/20 0.35
CCNC P24863 2/20 0.35
CDK8 P49336 2/20 0.35
CDK19 Q9BWU1 1/20 0.35
SCN9A Q15858 1/20 0.35
ADORA3 P0DMS8 2/20 0.35
ADORA1 P30542 2/20 0.35
OPRK1 P41145 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23580994 0.84 PDE4A (0.41) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL23580964 0.83 RORC (0.39) ADORA2AHCRTR1HCRTR2ADORA3ADORA1
SCHEMBL23580179 0.75 ATR (0.42) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL15765229 0.74 HPGD (0.51)
SCHEMBL2550739 0.72 SIRT6 (0.44) PDE4APDE4BPDE4CPDE4DADORA2A
SCHEMBL31479591 0.72 NPSR1 (0.41) OPRK1
SCHEMBL14721215 0.72 NPSR1 (0.41) OPRK1
SCHEMBL18335071 0.70 PLAU (0.43) OPRK1
SCHEMBL25689683 0.69 ALDH1A1 (0.57) PDE4APDE4BPDE4CPDE4DHCRTR1
SCHEMBL27020589 0.69 GRM5 (0.38) HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114945571-B Cyclic compounds and methods of use thereof 薛定谔公司 2025-02-25 CN disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
EP-4081526-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME Schrödinger, Inc. (US) 2022-11-02 EP disclosed
CN-114945571-A Cyclic compounds and methods of use thereof 薛定谔公司 2022-08-26 CN disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 WO disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME MALT1, FKBP1B, FKBP1A PDE4A 867/4885PDE4B 844/4885PDE4C 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.